摘要
目的探究米非司酮、依沙吖啶联合使用于瘢痕子宫中期妊娠引产中的临床疗效和安全性。方法将我院2010年5月~12月接收的150例引产妇随机分为对照组、观察组,每组75例。对照组孕妇单独使用依沙吖啶;观察组则联合使用米非司酮+依沙吖啶;通过观察对比两组孕妇的产程发动时间、产程、产后出血量、引产成功率和产道损伤程度等指标来分析米非司酮联合依沙吖啶在瘢痕子宫中孕引产中的临床疗效。结果观察组孕妇接受米非司酮+依沙吖啶联合使用后,孕妇的宫缩开始时间、出血量、产程和清宫率与对照组孕妇比较均显著下降,且二者差异显著,P<0.05;对照组产道受损的发生率为9.3%,明显高于观察组,且P<0.05;观察组的引产成功率为100%,较高于对照组(93.3%),但二者差异不显著,不具统计学意义。结论米非司酮、依沙吖啶在瘢痕子宫中期妊娠引产中的联合使用具安全性高、产程短、出血量少、产道损伤小等优点,作为一种科学、、有效的引产方法值得在临床上广泛使用。
Objective To explore the mifepristone Ethacridine used in combination in uterine scar trimester abortion, clinical efficacy and safety. Method 150 cases from May 2010 to December received cited maternal randomly divided into a control group, the observation group, each group of 75 cases. Pregnant women in the control group used alone the Ethacridine; the observation group jointly use mifepristone + Ethacridine; by observing the launch time, labor, postpartum hemorrhage, the rate of successful induction and birth canal damage degree of the birth process of comparing the two groups of pregnant women indicators to clinical efficacy analysis of mifepristone and Ethacridine uterine scar pregnancy induced labor. Results Pregnant women in the observation group received mifepristone + according to the the joint ethacridine use, pregnant women the contractions start time, the amount of bleeding, the birth process, and the Palace of Heavenly Purity rate with the control group of pregnant women were significantly lower, and the difference was significant, P〈0.05; damage to the birth canal of the control group, the rate was 9.3%, significantly higher than the observation group, P〈0.05; successful induction of the observation group was 100%, compared with the control group (93.3%), but the differencenot significant, not statistically significant. Conclusion Mifepristone, Ethacridine in uterine scar trimester abortion in joint use with high security, short birth process, the advantages of less bleeding, small birth canal injury, as a scientific and effective method of induction of laborworth in widespread clinical use.
出处
《中国医药指南》
2012年第30期50-51,共2页
Guide of China Medicine